You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Androgen Receptor Pathway Inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostate Cancer Trial in Boston, Brooklyn, New York (225Ac-J591, Pembrolizumab, Androgen receptor pathway inhibitor)

Recruiting
  • Prostate Cancer
  • Boston, Massachusetts
  • +3 more
Sep 20, 2021

Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of

Not yet recruiting
  • Triple Negative Breast Cancer
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 25, 2023

Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 Trial in Houston

Recruiting
  • Advanced Breast Carcinoma
  • +17 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Physical Function During ARSI Treatment

Recruiting
  • Advanced Prostate Carcinoma
  • androgen receptor signaling inhibitors
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Nov 8, 2022

Acne Vulgaris Trial in Stanford (Clascoterone 1% Top Cream, Vehicle)

Not yet recruiting
  • Acne Vulgaris
  • Stanford, California
    Stanford University
Jun 6, 2023

Androgen Deprivation Therapy, Prostate Cancer, Hypertension Trial (Gonadotropin-Releasing Hormone Agonist, Androgen receptor

Not yet recruiting
  • Androgen Deprivation Therapy
  • +4 more
  • Gonadotropin-Releasing Hormone Agonist
  • +2 more
  • (no location specified)
Jan 18, 2023

Prostatic Tumor Trial (AAA617, AAA517, Piflufolastat F 18)

Not yet recruiting
  • Prostatic Neoplasm
  • (no location specified)
Apr 27, 2023

Prostate Cancer, Malignant Tumor of Prostate, Secondary Malignant Tumor of Prostate Trial in Cleveland (drug, other, radiation)

Not yet recruiting
  • Prostate Cancer
  • +2 more
  • Androgen deprivation therapy (ADT)
  • +3 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center Seidman Cancer Cen
Nov 21, 2023

Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in United States (Biomarker Analysis,

Active, not recruiting
Has Results
  • Estrogen Receptor Negative
  • +6 more
  • Biomarker Analysis
  • +3 more
  • Birmingham, Alabama
  • +8 more
Feb 3, 2022

Castration-Resistant Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8 Trial in Buffalo

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 27, 2022

Malignant Tumor Trial in United States (Ketoconazole, Laboratory Biomarker Analysis, Placebo Administration)

Recruiting
  • Malignant Neoplasm
  • Danville, Illinois
  • +5 more
Apr 13, 2022

Chronic Lymphocytic Leukemia Trial in United States (ABT-199)

Completed
  • Chronic Lymphocytic Leukemia
  • La Jolla, California
  • +14 more
Dec 29, 2021

Triple Negative Breast Cancer Trial in United States (ribociclib, Bicalutamide)

Recruiting
  • Triple Negative Breast Cancer
  • Chicago, Illinois
  • +5 more
Oct 31, 2022

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, Best supportive/best standard of care

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jan 2, 2023

High-Risk Prostate Cancer Trial in Portland (Capivasertib, abiraterone acetate)

Not yet recruiting
  • High-Risk Prostate Cancer
  • Portland, Oregon
    VA Portland Health Care System, Portland, OR
Jan 17, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Worldwide (Acapatamab, Enzalutamide, Abiraterone)

Active, not recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Birmingham, Alabama
  • +13 more
Jun 20, 2022

Pancreatic Cancer Trial in Tampa (Enzalutamide, Gemcitabine, Nab-paclitaxel)

Completed
  • Pancreatic Cancer
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Aug 16, 2021

Triple Negative Breast Cancer Trial (Seviteronel-D (Seivteronel in combination with dexamethasone), Docetaxel)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Seviteronel-D (Seivteronel in combination with dexamethasone)
  • Docetaxel
  • (no location specified)
Sep 21, 2021

Prostate Cancer Trial in Chicago (Docetaxel, ADT, Abiraterone)

Not yet recruiting
  • Prostate Cancer
  • Chicago, Illinois
    Northwestern University
Sep 27, 2023

Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial (225Ac-PSMA-R2, 68Ga-PSMA-R2)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • (no location specified)
Aug 8, 2023

Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma Trial in Boston (CB-103,

Not yet recruiting
  • Adenoid Cystic Carcinoma
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 14, 2023

CNS Lymphoma Trial in Beijing (Zanubrutinib)

Recruiting
  • CNS Lymphoma
  • Beijing, Beijing, China
    Peking University People's Hospital
Aug 1, 2022

Prostate Cancer Metastatic Trial in France (Darolutamide 300 mg, Placebo, Androgen deprivation therapy)

Recruiting
  • Prostate Cancer Metastatic
  • Darolutamide 300 mg
  • +2 more
  • Avignon, France
  • +44 more
Sep 28, 2022

Breast Cancer With or Without BRCA Mutation

Recruiting
  • Breast Cancer
  • Androgen receptor status and BRCA mutation
  • Varanasi, UP, India
    Banaras Hindu University
Jun 2, 2022

HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma Trial in Houston (L-NMMA)

Recruiting
  • HER2-negative Breast Cancer
  • +3 more
  • Houston, Texas
    Houston Methodist Neal Cancer Center
Jan 12, 2023